with presence in approx.
$29.4BN1 USD revenue
Planned R&D investment of
in FY2022 to support
our innovative pipeline
Approx. 40 new molecular
in the pipeline
Including 10 late-stage
in the 2021 Access to
Medicine (AtM) Index
Industry leader in
"Governance of Access"
Global Top Employer
in value chain in FY2020
On track for carbon zero
status by 2040
2x (i.e. "low-twos")
Net Debt / Adjusted
EBITDA2 ratio in
15 experienced global leaders,
including 11 independent
As of March 2022. References: FY2021 Investor Presentation; Corporate Overview
1USD included for reference, calculated at JPY/USD of 121.44
2Non-IFRS measure. Further information on this and other Takeda Non-IFRS measures is posted on Takeda’s investor relations website
3As defined by Tokyo Stock Exchange Securities Listing Regulations
Check back for event calendar updates or sign up for email alerts straight to your inbox.
Find out how our financial and other impacts are creating value in the short, medium and long term, and the focus areas we believe are most important for the stakeholders and communities we serve. READ MORE
Our world-class R&D engine is focused on developing medicines and vaccines that will have a lasting impact on society and can make a critical difference to the lives of patients with limited or no options for treatment.
You may contact a licensed stockbroker or go through any registered broker-dealer to purchase shares of Takeda.
Takeda’s common shares are traded on the Tokyo Stock Exchange using stock code “4502.” Our ADSs are traded on the New York Stock Exchange using the symbol “TAK”.
An American Depositary Receipt (ADR) is a certificate representing ownership of American Depositary Shares (ADSs) in a non-U.S. corporation. They include the right to attend and vote at AGMs, the receipt of dividends, and other common shareholder rights. One ADS represents 0.5 shares of Takeda’s common stock.
Takeda’s dividend payments have historically been issued on a semi-annual basis in June and December. The record date for year-end dividends is March 31 of each year. The record date for interim dividends is September 30 of each year.
Takeda’s fiscal year ends on March 31st. You can find our earnings materials and dates on our financial results webpage.
Takeda’s official reporting currency is the yen.
Takeda follows the International Financial Reporting Standards, or IFRS, for its financial reporting.
To send a comment or question to Takeda Pharmaceutical Company Limited, please visit: https://www.takeda.com/who-we-are/contact-us/
To subscribe to email alerts from Takeda, please use the form at the top of this page.
For feedback or inquiries, please visit https://www.takeda.com/who-we-are/contact-us/